# Retrotope

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/retrotope

- Industry: Biotechnology
- Headquarters: Los Altos, US
- Website: www.retrotope.com
- Total disclosed funding: $24M
- Latest round: Series C (Jul 12, 2019)
- Investors on record: 9

## About

Retrotope Inc. specializes in developing innovative biopharmaceutical solutions that target mitochondrial dysfunction, aiming to enhance health and longevity through advanced medical technologies.Founded in 2006, Retrotope Inc. operates from its headquarters in Los Altos, US. The company focuses on developing therapies for mitochondrial diseases and has engaged in 15 deals since its inception. Mikhail Shchepinov, the founder, has a history of involvement in biotechnology, marking significant contributions to the sector. The most recent funding round was a Series D in May 2021, raising USD 12.20 mn, bringing the total amount raised to USD 12.20 mn with a current valuation of USD 168.266 mn.Retrotope Inc. is set to deliver products and services designed to address the specific needs of the biopharmaceutical market. The company’s core product lines are focused on creating effective solutions for various healthcare challenges, enhancing patient outcomes, and potentially advancing medical treatments through innovative technologies.Retrotope Inc. has structured its revenue model around facilitating transactions within the biopharmaceutical sector, likely engaging in B2B and direct-to-consumer sales. The company is expected to offer tailored pricing plans for its innovative therapies, fostering long-term customer relationships and repeat business, although specific revenue figures have not been disclosed.The most recent Series D funding round in May 2021, which raised USD 12.20 mn, positions Retrotope Inc. to further develop its pipeline of innovative therapies aimed at mitochondrial dysfunction. Plans for future growth include expanding market reach and launching new products in targeted regions, although specific details about product releases and geographic expansion plans have not been disclosed. The funding will support these strategic initiatives, aligning with the company's commitment to advancing health through biopharmaceutical innovations.

## Funding rounds

- Series C, Jul 12, 2019, $12M — 5Y Capital, Mehta Partners
- Series C, May 15, 2019, $2.8M — Morningside, Mehta Partners
- Series C, Feb 27, 2019, $2.2M — Morningside, Mehta Partners
- Series C, Nov 30, 2018, $7.3M — Morningside Private Investors, Mehta Partners
- Series B, Jan 17, 2015, $0.2M — Life Science Angels, Inc., SDL Ventures, Johnston Associates, Green Park & Golf Ventures, North Texas Angels Network

## Investors

- Life Science Angels, Inc. — Series B
- SDL Ventures (https://capitalatlas.ai/funds/sdl-ventures) — Series B
- Johnston Associates — Series B
- Green Park & Golf Ventures (https://capitalatlas.ai/funds/green-park-golf-ventures) — Series B
- North Texas Angels Network — Series B
- Morningside Private Investors (https://capitalatlas.ai/funds/morningside-private-investors) — Series C
- Mehta Partners — Series C
- Morningside (https://capitalatlas.ai/funds/morningside) — Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series C